US2023226153A1PendingUtilityA1

Stem cells for transplantation and manufacturing method therefor

76
Assignee: NAT CENTER NEUROLOGY & PSYCHIATRYPriority: May 22, 2013Filed: Jan 30, 2023Published: Jul 20, 2023
Est. expiryMay 22, 2033(~6.8 yrs left)· nominal 20-yr term from priority
Inventors:Takashi OkadaYuko KasaharaShinichi Takeda
A61K 38/2066C12N 5/0663A61L 27/3834A61K 35/28C07K 14/5428C12N 5/0662C12N 7/00C12N 15/86C12N 2501/231C12N 2510/02A61K 48/00A61P 37/06A61K 39/001A61K 2039/577A61K 2039/552A61P 1/16A61P 19/04A61P 21/00A61P 25/00A61P 9/00C12N 2510/00C12N 2750/14143C12N 2750/14171
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.

Claims

exact text as granted — not AI-modified
1 - 11 . (canceled) 
     
     
         12 . A composition comprising human mesenchymal stem cells (hMSCs) and a viral immunogen, wherein, when the composition is administered to a subject, it suppresses the subject's immune response to the viral immunogen. 
     
     
         13 . The composition according to  claim 12 , wherein the viral immunogen is from an adenovirus, adeno-associated virus (AAV), retrovirus, or lentivirus. 
     
     
         14 . The composition according to  claim 13 , wherein the viral immunogen is from an AAV or adenovirus. 
     
     
         15 . The composition according to  claim 12 , wherein the viral immunogen is a recombinant viral immunogen. 
     
     
         16 . The composition according to  claim 15 , wherein the recombinant viral immunogen is a recombinant virus for expression of IL-10. 
     
     
         17 . The composition according to  claim 12 , wherein the composition induces tolerance to the viral immunogen when administered to the subject. 
     
     
         18 . The composition according to  claim 12 , wherein the hMSCs are recombinant hMSCs. 
     
     
         19 . The composition according to  claim 18 , wherein the recombinant hMSCs overexpress exogenous IL-10. 
     
     
         20 . The composition according to  claim 12 , further comprising recombinant IL-10. 
     
     
         21 . A method for reducing an immune response to a viral immunogen in a subject in need thereof, the method comprising:
 administering to the subject:   (i) human mesenchymal stem cells (hMSCs); and   (ii) the viral immunogen, whereby the immune response to the viral immunogen is suppressed.   
     
     
         22 . The method according to  claim 21 , wherein the viral immunogen is from an adenovirus, adeno-associated virus (AAV), retrovirus, or lentivirus. 
     
     
         23 . The method according to  claim 21 , wherein the viral immunogen is a recombinant viral immunogen. 
     
     
         24 . The method according to  claim 23 , wherein the recombinant viral immunogen is a recombinant virus for expression of IL-10. 
     
     
         25 . The method according to  claim 22 , wherein the viral immunogen is from an AAV or adenovirus. 
     
     
         26 . The method according to  claim 21 , wherein suppression of the immune response comprises induction of tolerance to the viral immunogen. 
     
     
         27 . The method according to  claim 21 , wherein the hMSCs are recombinant hMSCs. 
     
     
         28 . The method according to  claim 27 , wherein the recombinant hMSCs overexpress exogenous IL-10. 
     
     
         29 . The method according to  claim 21 , wherein the hMSCs and the viral immunogen are co-administered at the same time. 
     
     
         30 . The method according to  claim 21 , wherein the hMSCs and the viral immunogen are administered sequentially. 
     
     
         31 . The method according to  claim 21 , further comprising administering recombinant IL-10.

Join the waitlist — get patent alerts

Track US2023226153A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.